Tolvaptan-d7 |
| カタログ番号GC48186 |
Tolvaptan-D7 (OPC-41061-D7) は、Tolvaptan とラベル付けされた重水素です。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1246818-18-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Tolvaptan-d7 is intended for use as an internal standard for the quantification of tolvaptan by GC- or LC-MS. Tolvaptan is a nonpeptide vasopressin V2 receptor antagonist (IC50 = 3 nM for rat receptor) and a diuretic agent.1 It is selective for V2 over V1 receptors (IC50 = 0.58 μM). Tolvaptan increases urine volume by 3-fold in rats when administered at a dose of 0.54 mg/kg. It also reduces left ventricular end-systolic volumes and improves left ventricular ejection fraction in a rat model of myocardial infarction.2 Formulations containing tolvaptan have been used to treat hyponatremia.
1.Kondo, K., Ogawa, H., Yamashita, H., et al.7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonistBioorg. Med. Chem.7(8)1743-1754(1999) 2.Yamazaki, T., Nakamura, Y., Shiota, M., et al.Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in ratsJ. Pharmacol. Sci.123(1)58-66(2013)
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *